Intensity Therapeutics (INTS) to Release Quarterly Earnings on Thursday

Intensity Therapeutics (NASDAQ:INTS) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Intensity Therapeutics to post earnings of ($0.8725) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:00 PM ET.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.12. On average, analysts expect Intensity Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Intensity Therapeutics Price Performance

Intensity Therapeutics stock opened at $4.33 on Thursday. The firm has a 50-day moving average price of $4.30 and a 200-day moving average price of $6.03. The firm has a market capitalization of $11.69 million, a PE ratio of -0.76 and a beta of 2.78. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in Intensity Therapeutics in the 4th quarter valued at about $26,000. Corient Private Wealth LLC bought a new position in Intensity Therapeutics in the 4th quarter worth about $41,000. State Street Corp increased its position in shares of Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after acquiring an additional 201,357 shares during the period. 3.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on INTS shares. Wall Street Zen upgraded shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.50.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.